Commonwealth Equity Services LLC Has $2.58 Million Stock Holdings in Schrödinger, Inc. (NASDAQ:SDGR)

Commonwealth Equity Services LLC increased its position in shares of Schrödinger, Inc. (NASDAQ:SDGR – Get Rating) by 79.5% during the 4th quarter, HoldingsChannel reports. The fund owned 137,919 shares of the company’s stock after purchasing an additional 61,071 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Schrödinger were worth $2,577,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in SDGR. US Bancorp DE lifted its stake in Schrödinger by 69.2% in the first quarter. US Bancorp DE now owns 1,932 shares of the company’s stock valued at $66,000 after buying an additional 790 shares during the period. IFP Advisors Inc lifted its stake in Schrödinger by 294.7% in the third quarter. IFP Advisors Inc now owns 3,750 shares of the company’s stock valued at $107,000 after buying an additional 2,800 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of Schrödinger by 240.2% in the third quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock worth $160,000 after acquiring an additional 4,499 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Schrödinger by 124.8% in the third quarter. SG Americas Securities LLC now owns 8,978 shares of the company’s stock worth $224,000 after acquiring an additional 4,985 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Schrödinger by 21.1% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,887 shares of the company’s stock worth $241,000 after acquiring an additional 2,249 shares in the last quarter. Institutional investors and hedge funds own 68.70% of the company’s stock.

Schrödinger Price Performance

Shares of Schrödinger stock opened at $27.68 on Tuesday. Schrödinger, Inc. has a one year low of $15.85 and a one year high of $35.24. The stock’s 50-day moving average is $27.09 and its 200 day moving average is $23.32. The firm has a market cap of $1.97 billion, a price-to-earnings ratio of 212.92 and a beta of 1.06.

Schrödinger (NASDAQ:SDGR – Get Rating) last announced its quarterly earnings results on Tuesday, February 28th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.11. The business had revenue of $56.84 million for the quarter, compared to analyst estimates of $48.69 million. Schrödinger had a negative return on equity of 27.77% and a net margin of 7.30%. On average, sell-side analysts expect that Schrödinger, Inc. will post 0.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Piper Sandler began coverage on Schrödinger in a report on Friday, May 5th. They set an “overweight” rating and a $60.00 price objective for the company. BMO Capital Markets cut their price objective on Schrödinger from $83.00 to $78.00 and set an “outperform” rating for the company in a research report on Wednesday, March 1st. Morgan Stanley lifted their price target on Schrödinger from $38.00 to $39.00 and gave the stock an “equal weight” rating in a report on Friday, March 10th. Finally, Citigroup dropped their price target on Schrödinger from $52.00 to $50.00 in a report on Monday, May 8th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $50.00.

About Schrödinger

(Get Rating)

Schrödinger, Inc, together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries.